Please ensure Javascript is enabled for purposes of website accessibility
ORIGINAL PAPER
Assessment of clinical risk factors for drug-resistant epilepsy in children and teenagers
 
More details
Hide details
 
Submission date: 2014-05-20
 
 
Final revision date: 2014-07-21
 
 
Acceptance date: 2014-08-08
 
 
Publication date: 2014-09-19
 
 
Medical Studies 2014;30(3):141-147
 
KEYWORDS
TOPICS
ABSTRACT
Introduction: Epilepsy is one of the most common neurological illnesses occurring in children. In approximately 20–30% of cases it is drug-resistant.
Aim of the research: To assess the already-known risk factors, analyse the rarely described ones, and find new causes of epilepsy drug resistance in children, taking into account the level of impact of each factor.
Material and methods: The study comprised 152 of all 383 children hospitalised in 2012 at the Neurology Department of the Polish Mother’s Memorial Hospital in Lodz due to epilepsy. Based on medical documentation, neurological examination, and our own questionnaire, we divided patients into two groups: drug-resistant epilepsy or drug-sensitive epilepsy. We compared the type, level of influence, and prevalence of different factors. For statistical analysis, the 2 test was used. Statistical significance was set at p < 0.05.
Results: Drug-resistant epilepsy was found in 64 patients (42.1%), and drug-sensitive epilepsy was found in 88 patients (57.9%). Factors that were most probable to cause drug resistance included: high prevalence of seizures (Cramer’s V = 0.66), type of epileptic syndrome (V = 0.62), psychomotor developmental delay (V = 0.62), and occurrence of status epilepticus (V = 0.6). Factors such as infections of CNS in early childhood, repeated severe infections of airways in childhood, and mother’s infectious diseases with high fever during pregnancy were rare or non occurring (Cramer’s V = 0.41, 0.32, and 0.31, respectively).
Conclusions: The study confirmed the previously known causes of drug resistance and indicated the significance of underestimated inflammatory and infectious factors involving pyrexia, in children and also in mothers during pregnancy.
REFERENCES (40)
1.
br>Wendorff J. Czynniki ryzyka padaczki lekoopornej u dzieci [Polish]. Klin Pediatr 2003; 11: 251-5.
 
2.

Jóźwiak S. Współczesne poglądy na klasyfikację, patogenezę i postępowanie w padaczce lekoopornej [Polish]. Wiad Lek 2007; 60: 258-64.
 
3.

Kwan P, Arzimanoglou A, Berg AT, et al. Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia 2010; 51: 1069-77.
 
4.

Wiebe S. Definition of drug resistant epilepsy: is it evidence based? Epilepsia 2013; 54 Suppl 2: 9-12.
 
5.

Wypych M, Andrzejczak-Sobocińska A, Tomalska J. Padaczka lekooporna – kryteria rozpoznania i leczenie [Polish]. Neurologia 2005; 10: 58-63.
 
6.

Sillanpaa M. Remission of seizures and predictors of intractability in long – term follow up. Epilepsy 1993; 34: 930-6.
 
7.

Wirrell E, Camfield C, Camfield P, et al. Prognostic significance of failure of the initial antiepileptic drug in children with absence epilepsy. Epilepsia 2001; 42: 760-3.
 
8.

Ramos-Lizana J, Aguilera-López P, Aguirre-Rodriguez J, et al. Early prediction of refactory epilepsy in childhood. Seizure 2009; 18: 412-6.
 
9.

Sillanpaa M, Schmidt D. Naturial history of treated childhood-onset epilepsy: prospective, long-term population-based study. Brain 2006; 129: 617-24.
 
10.

Mohanraj R, Brodie MJ. Diagnosing refractory epilepsy: response to sequential treatment schedules. Eur J Neurol 2006; 13: 277-82.
 
11.

Oskoui M, Webster RI, Zhand X, et al. Factors predictive of outcome in childhood epilepsy. J Child Neurol 2005; 2011: 898-904.
 
12.

Thang-Wai R, Oskoui M, Webster R, et al. Outcomes in pediatric epilepsy: seeing through the fog. Pediatr Neurol 2005; 33: 244-50.
 
13.

Gururaj A, Sztriha L, Hertecant J, et al. Clinical predictors of intractable childhood epilepsy. J Psychosom Res 2006; 61: 343-7.
 
14.

.French JA. Refractory epilepsy: clinical overview. Epilepsia 2007; 48 Suppl 1: 3-7.
 
15.

Berg AT, Shinnar S, Levy SR, et al. Early development of intractable epilepsy in children: a prospective study. Neurology 2001; 56: 1445-52.
 
16.

Ohtsuka Y, Yoshinaga H, Kobayashi K, et al. Predictors and underlying causes of medically intractable localization-related epilepsy in childhood. Pediatr Naurol 2001; 24: 209-13.
 
17.

Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med 2000; 342: 314-9.
 
18.

Akhondian J, Heydarian F, Jafar SA. Predictive factors of pediatric intractable seizures. Arch Iran Med 2006; 9: 236-9.
 
19.

Berg AT, Levy SR, Navotny EJ, et al. Predictors of intractable epilepsy in childhood: a case control study. Epilepsia 1996; 37: 24-30,.
 
20.

Geerts A, Arts WF, Stroink H, et al. Course and outcome of childhood epilepsy: 15-year follow-up of the Dutch Study of epilepsy in childhood. Epilepsia 2010; 51: 1189-97.
 
21.

Schiller Y, Najjar Y. Quantifying the response to antiepileptic drugs: effect of past treatment history. Neurology 2008; 70: 54-65.
 
22.

Berg AT, Vickrey BG, Testa FM, et al. How long does it take for epilepsy to become intractable? A prospective investigation. Ann Neurol 2006; 60: 73-9.
 
23.

Kwong KL, Sung WY, Wong SN, et al. Early predictors of medical intractability in childhood epilepsy. Pediatr Neurol 2003; 29: 46-52.
 
24.

Chawla S, Aneja S, Kashyap R, et al. Etiology and clinical predictors of intractable epilepsy. Pediatr Neurol 2002; 3: 186-91.
 
25.

Ramos-Lizana J, Rodriguez-Lucenilla M, Aguilera-López P,et al. A study of drug-tesistand childhood epilepsy testing the new ILAE criteria. Seizure 2012; 21: 266-72.
 
26.

Camfield PR, Camfield CS, Gordon K, Dooley JM. If a first antiepileptic drug fails to control a child’s epilepsy, what are the chances of success with the next drug? J Pediatr 1997; 131: 821-4.
 
27.

Fastenau PS, Johnson CS, Perkins SM, et al. Neruopsychological status at seizure onset in children: risk factors for early cognitive deficits. Neurology 2009; 73: 526-34.
 
28.

Tiege X, Laufs H, Boyd SG, et al. EEG-fMRI in children with pharmacoresistant focal epilepsy. Epilepsia 2007; 48: 385-9.
 
29.

Aldenkamp AP, Arends J, Verspeek S, et al. The cognitive impact of epileptiform EEG-discharges; relationship with type of cognitive task. Child Neuropsychol 2004; 10: 297-305.
 
30.

Jóźwiak S, Kotulska K, Domańska-Pakieła D, et al. Antiepileptic treatment before the onset of seizures reduces epilepsy severity and risk of mental retardation in infants with tuberous sclerosis complex. Eur J Paediatr Neurol 2011; 15: 424-31.
 
31.

Bombardieri R, Pinci M, Moavero R, et al. Early control of seizures improves long-term outcome in children with tuberous sclerosis complex. Eur J Paediatr Neurol 2010; 14: 146-9.
 
32.

Guerrini R, Holthausen H, Parmegani L, et al. Epilepsy and malformations of cerebral cortex. In: Epileptic syndromes in infancy, childhood and adolescence (3rd ed.). Roger J, Bureaum M, Drawet C, et al. John Libbey. London 2002; 457-79.
 
33.

Go C, Snead OC. Pharmacologically intractable epilepsy in children: diagnosis and preoperative evaluation. Neurosurg Focus 2008; 25: E2.
 
34.

Melila M, Suriadi-Yukitoshi T, Shigeko N, et al. Zaburzenia funkcji bariery krew – mózg u chorych z padaczką po przebytym zapaleniu mózgu [Polish]. Epileptologia 2012; 20: 23-4.
 
35.

Marchi N, Granata T, Janigro D. Inflammatory pathways of seizure disorders. Trends Neurosci 2014; 37: 55-6.
 
36.

Geerts A, Arts WF, Stroink H, et al. Course and outcome of childhood epilepsy: a 15-year follow-up of the Dutch Study of Epilepsy in Childhood. Epilepsia 2010; 51: 1189-97.
 
37.

Najjar S, Pearlman D, Miller DC, et al. Refractory epilepsy associated with microglial activation. Neurologist 2011; 17: 249-54.
 
38.

van Vliet EA, da Costa Araujo S, Redeker S, et al. Bloodbrain barrier leakage maylead to progression of temporal lobe epilepsy. Brain 2007; 130: 521-34.
 
39.

Billian AD, Witters P, Cenlemans B, et al. Intravenous immunoglobulins in refractory childhoodonset epilepsy: effects on seizure frequency, EEG activity and cerebrospinal fluid cytokine profile. Epilepsia 2007; 48: 1739-49.
 
40.

Kalinin W, Zemlianaja A, Żelaznowa W, et al. Neurobiologiczne i kliniczne czynniki rokownicze remisji i skuteczności leczenia przeciwpadaczkowego w padaczkach częściowych [Polish]. J Epileptol 2013; 21: 7-10.
 
eISSN:2300-6722
ISSN:1899-1874
Journals System - logo
Scroll to top